• 1
    American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161: 646664.
  • 2
    Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998;73: 10851101.
  • 3
    Nagai S, Kitaichi M, Izumi T. Classification and recent advances in idiopathic interstitial pneumonia. Curr Opin Pulm Med 1998;4: 256260.
  • 4
    du Bois RM. Diffuse lung disease: a view for the future. Sarcoidosis Vasculitis Diffuse Lung Dis 1997;14: 2330.
  • 5
    Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazalaar HD, Schroeder DR et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157: 199203.
  • 6
    Mason RJ, Schwartz MI, Hunninghake GW, Musson RA. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am J Respir Crit Care Med 1999;160: 17711777.
  • 7
    Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345: 517525.
  • 8
    Katzenstein A-L, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157: 13011315.
  • 9
    Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994;150: 967972.
  • 10
    Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979–1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996;153: 15481552.
  • 11
    Johnston IDA, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997;52: 3844.
  • 12
    Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med 1997;156: 939942.
  • 13
    Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134: 136151.
  • 14
    Kuhn C III, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989;140: 16931703.
  • 15
    Kuhn C III, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138: 12571265.
  • 16
    Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol 1996;11: 463483.
  • 17
    Kawanami O, Ferrans VJ, Crystal RG. Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest 1982;46: 3953.
  • 18
    Kasper M, Koslowski R, Luther T, Schuh D, Muller M, Wenzel KW. Immunohistochemical evidence for loss of ICAM-1 by alveolar epithelial cells in pulmonary fibrosis. Histochem Cell Biol 1995;104: 397405.
  • 19
    Kallenberg CG, Schilizzi BM, Beaumont F, De Leij L, Poppema S, The TH. Expression of class II major histocompatibility complex antigens on alveolar epithelium in interstitial lung disease: relevance to pathogenesis of idiopathic pulmonary fibrosis. J Clin Pathol 1987;40: 725733.
  • 20
    McCormack FX, King TE Jr, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis: abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis 1991;144: 160166.
  • 21
    McCormack FX, King TE Jr, Bucher BL, Nielsen L, Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;152: 751759.
  • 22
    Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989;140: 513524.
  • 23
    Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor β and tumor necrosis factor α. Am J Respir Crit Care Med 1995;152: 21632169.
  • 24
    Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumour necrosis factor-α in cryptogenic fibrosing alveolitis. Histopathology 1993;22: 343347.
  • 25
    Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5: 155162.
  • 26
    Schonherr E, Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol 2000;7: 89101.
  • 27
    Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001;21: 351372.
  • 28
    Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000;105: 193204.
  • 29
    Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002;3: 311.
  • 30
    Uhal BD, Joshi I, True AL, Mundle S, Raza A, Pardo A et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995;269: L819L828.
  • 31
    Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998;275: L1192L1199.
  • 32
    Leslie KO, Mitchell J, Low R. Lung myofibroblasts. Cell Motil Cytoskeleton 1992;22: 9298.
  • 33
    Furuie H, Yamasaki H, Suga M, Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997;10: 787794.
  • 34
    Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18: 6065.
  • 35
    Kunkel SL, Lukacs NW, Strieter RM, Chensue SW. Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis 1996;13: 120128.
  • 36
    Martinez JA, King TE Jr, Brown K, Jennings CA, Borish L, Hortenson RL et al. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol 1997;273: L676L683.
  • 37
    Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999;5: 285294.
  • 38
    Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341: 12641269.
  • 39
    Michaelson JE, Aguayo SM, Roman J. Idiopathic pulmonary fibrosis: a practical approach for diagnosis and management. Chest 2000;118: 788794.
  • 40
    Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980;35: 171180.
  • 41
    Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976;85: 769788.
  • 42
    King TE Jr. Idiopathic pulmonary fibrosis. In: SchwarzMI, KingTEJr, editors. Interstitial lung disease, 3rd edn. Hamilton: BC Decker, 1998: 597644.
  • 43
    Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996;347: 284289.
  • 44
    Panos RG, Mortenson R, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88: 396404.
  • 45
    Hanley ME, King TE Jr, Schwarz MI, Watters LC, Shen AS, Cherniack RM. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 1991;144: 11021106.
  • 46
    Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest 1979;63: 665676.
  • 47
    Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978;298: 934939.
  • 48
    Orens JB, Kazerooni EA, Martinez FJ, Curtis JL, Gross BH, Flint A et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy: a prospective study. Chest 1995;108: 109115.
  • 49
    Guerry-Force ML, Mueller NL, Wright JL, Wiggs B, Coppin C, Pare PD et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis 1987;135: 705712.
  • 50
    Grenier P, Valeyre D, Cluzel P, Brauner MW, Lenoir S, Chastand C. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology 1991;179: 123132.
  • 51
    Mathieson JR, Mayo JR, Staples CA, Muller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989;171: 111116.
  • 52
    Tung KT, Wells AU, Rubens MB, Kirk JM, du Bois RM, Hansell DM. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax 1993;48: 334338.
  • 53
    Akira M, Sakatani M, Ueda E. Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology 1993;189: 687691.
  • 54
    Nishimura K, Kitaichi M, Izumi T, Nagai S, Kanaoka M, Itoh H. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 1992;182: 337342.
  • 55
    Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 1997;169: 977983.
  • 56
    Xaubet A, Agusti C, Luburich P, Roca J, Monton C, Ayuso MC et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158: 431436.
  • 57
    Mino M, Noma S, Kobashi Y, Iwata T. Serial changes of cystic air spaces in fibrosing alveolitis: a CT-pathological study. Clin Radiol 1995;50: 357363.
  • 58
    Wells AU, Rubens MB, du Bois RM, Hansell DM. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Roentgenol 1993;161: 11591165.
  • 59
    Hartman TE, Primack SL, Kang EY, Swenzen SJ, Hansell DM, McGuinness G et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT. Chest 1996;110: 378382.
  • 60
    American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the idiophatic interstitial pneumonias. Am J Respir Crit Care Med 2002;165: 277304.
  • 61
    Leung AN, Miller RR, Muller NL. Parenchymal opacification in chronic infiltrative lung diseases: CT-pathologic correlation. Radiology 1993;188: 209214.
  • 62
    Müller NL, Staples CA, Miller RR, Vedal S, Thurlbeck WM, Ostrow DN. Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 1987;165: 731734.
  • 63
    Hunninghake G, Schwartz D, King T et al. Open lung biopsy in IPF[abstract]. Am J Respir Crit Care Med 1998;157(Suppl.):A277.
  • 64
    Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new-onset idiophatic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999;116: 11681174.
  • 65
    Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Hegele R et al. Utility of a lung biopsy for the diagnosis of idiophatic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164: 193196.
  • 66
    Klech H, Hutter C. Clinical guidelines and indications for bronchoalveolar lavage (BAL): report of the European Society of Pneumology Task Force on BAL. Eur Respir J 1990;3: 937974.
  • 67
    American Thoracic Society. American Thoracic Society statement: clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 1990;142: 481486.
  • 68
    Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149: 450454.
  • 69
    Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis relationships of pulmonary physiology and bronchoalveolar lavage to treatment and prognosis. Am Rev Respir Dis 1981;124: 18.
  • 70
    Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987;135: 696704.
  • 71
    Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984;310: 154166, 235–244.
  • 72
    Crystal RG, Gadek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghake GW. Interstitial lung disease: current concepts of pathogenesis, staging, and therapy. Am J Med 1981;70: 542568.
  • 73
    Haslam PL, Turton CWG, Heard B, Lukoszek A, Collins JV, Salsbury AJ et al. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 1980;35: 918.
  • 74
    Haslam PL, Turton CWG, Lukoszek A, Salsbury AJ, Dewar A, Collins JV et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980;35: 328339.
  • 75
    Boomars KA, Wagenaar SS, Mulder PGH, van Velzen-Blad H, van den Bosch JMM. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 1995;50: 10871092.
  • 76
    Davis GS. Bronchoalveolar lavage in interstitial lung disease. Semin Respir Crit Care Med 1994;15: 3760.
  • 77
    Haviv YS, Breuer R, Sviri S, Libson E, Safadi R. CT-guided biopsy of peripheral lung lesions associated with BOOP. Eur J Med Res 1997;2: 4446.
  • 78
    Rizzato G. The role of thoracic surgery in diagnosing interstitial lung disease. Curr Opin Pulm Med 1999;5: 284286.
  • 79
    Ayed AK, Raghunathan R. Thoracoscopy versus open lung biopsy in the diagnosis of interstitial lung disease: a randomised controlled trial. J R Coll Surg Edinb 2000;45: 159163.
  • 80
    Flint A, Martinez FJ, Young ML, Whyte RI, Toews GB, Lynch JP III. Influence of sample number and biopsy site on the histologic diagnosis of diffuse lung disease. Ann Thorac Surg 1995;60: 16051607.
  • 81
    Newman SL, Michel RP, Wang NS. Lingular lung biopsy: is it representative? Am Rev Respir Dis 1985;132: 10841086.
  • 82
    Wetstein L. Sensitivity and specificity of lingular segmental biopsies of the lung. Chest 1986;90: 383386.
  • 83
    Miller RR, Nelems B, Müller NL, Evans KG, Ostrow DN. Lingular and right middle lobe biopsy in the assessment of diffuse lung disease. Ann Thorac Surg 1987;44: 269273.
  • 84
    Lynch DA, Rose C, Way DE, King TE Jr. Hypersensitivity pneumonitis: sensitivity of high resolution CT in a population-based study. Am J Roentgenol 1992;159: 469472.
  • 85
    Johnston ID, Gomm SA, Kalra S, Woodcock AA, Evans CC, Hind CR. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom. Eur Respir J 1993;6: 891893.
  • 86
    Bensard DD, McIntyre RC Jr, Waring BJ, Simon JS. Comparison of video thoracoscopic lung biopsy to open lung biopsy in the diagnosis of interstitial lung disease. Chest 1993;103: 765770.
  • 87
    Agostini C, Albera C, Bariffi F, De Palma M, Harari S, Lusuardi M et al. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis 2001;56: 364368.
  • 88
    Colby TV, Carrington CB. Interstitial lung disease. In: ThurlbeckWM, ChurgAM, editors. Pathology of the lung, 2nd edn. New York: Thieme Medical Publishers, 1995: 589737.
  • 89
    Katzenstein AL, Askin FB. Surgical pathology of non-neoplastic lung disease, 3rd edn. Philadelphia: WB Saunders, 1997.
  • 90
    Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic non-specific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000;24: 1933.
  • 91
    Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Müller NL, King TE Jr. Idiopathic interstitial pneumonia and other diffuse parenchymal lung disease. In: Non-neoplastic disorders of the lower respiratory tract. Washington: American Registry of Pathology and the Armed Forces Institute of Pathology, 2001.
  • 92
    Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997;168: 7983.
  • 93
    Kitaichi M. Pathologic features and the classification of interstitial pneumonia of unknown etiology. Bull Chest Dis Res Inst Kyoto Univ 1990;23: 118.
  • 94
    Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993;103: 18081812.
  • 95
    Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989;64: 13731380.
  • 96
    Katzenstein A-L, Myers JL, Mazur MT. Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1994;10: 256267.
  • 97
    Katzenstein A-L, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am J Surg Pathol 1994;18: 136147.
  • 98
    Epler GR. Heterogeneity of bronchiolitis obliterans organizing pneumonia. Curr Opin Pulm Med 1998;4: 9397.
  • 99
    Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH et al. Histopathologic variability in usual and non-specific interstitial pneumonias. Am J Respir Crit Care Med 2001;164: 17221727.
  • 100
    Winterbauer RH, Hammar SP, Hallman KO, Hays JE, Pardee NE, Morgan EH et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednizone/azathioprine. Am J Med 1978;65: 661672.
  • 101
    Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron J, Ackerson L et al. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1991;144: 892900.
  • 102
    McAnulty RJ, Laurent GJ. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol 1995;3: 96107.
  • 103
    Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996;110: 10581067.
  • 104
    British Thoracic Society Standard Sub-committee. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax 1999;54: S1S14.
  • 105
    Selman M. Idiopathic pulmonary fibrosis challenges for the future. Chest 2001;120: 810.
  • 106
    Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351: 2427.
  • 107
    Lynch JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155: 395420.
  • 108
    Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd, 2003.
  • 109
    Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972;27: 535542.
  • 110
    Lee JS, Im JG, Ahn JM, Kim YM, Han MC. Fibrosing alveolitis: prognostic implication of ground-glass attenuation at high-resolution CT. Radiology 1992;184: 451454.
  • 111
    Cegla, UH. Treatment of idiopathic fibrosing alveolitis: therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy. Schweiz Med Wochenschr 1977;107: 184187.
  • 112
    Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44: 280288.
  • 113
    Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144: 291296.
  • 114
    Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992;102: 10901094.
  • 115
    Dayton CS, Schwartz DA, Helmers RA, Pueringer RJ, Gilbert JR, Merchant RK et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993;103: 6973.
  • 116
    Douglas WW, Ryu JH, Swensen J, Offord KP, Schroeder DR, Caron GM et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Am J Respir Crit Care Med 1998;158: 220225.
  • 117
    Selman M, Carrillo G, Salas J, Padilla RD, Perez-Chavira R, Sansores R et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998;114: 507512.
  • 118
    Raghu G, Johnson C, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective open label study. Am J Respir Crit Care Med 1999;159: 10611069.
  • 119
    Herbert CM, Lindberg KA, Jayson MI, Bailey AJ. Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine. Lancet 1974;1: 187192.
  • 120
    Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw 1996;7: 363374.
  • 121
    Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: down-regulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21: 791808.
  • 122
    Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350: 125133.
  • 123
    Arnaud P. The interferons: pharmacology, mechanism of action, tolerance and side effects. Rev Med Intern 2002;23: 449458.
  • 124
    Honoré I, Nunes H, Groussard O, Kambouchner M, Chambellan A, Aubier M et al. Acute respiratory failure after interferon-γ therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003;167: 953957.
  • 125
    American Thoracic Society. Lung transplantation. Am Rev Respir Dis 1993;147: 772777.
  • 126
    American Thoracic Society. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998;158: 335339.
  • 127
    Egan JJ, Hasleton PS. Cryptogenic fibrosing alveolitis: diagnosis and treatment. Hospital Medicine 1998;59: 364368.
  • 128
    Sulica R, Teirstein A, Padilla ML. Lung transplantation in interstitial lung disease. Curr Opin Pulm Med 2001;7: 314321.
  • 129
    Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997;155: 789818.
  • 130
    Mogulkoc N, Brutsche MH, Bishop PW, Murby B, Greaves MS, Horrocks AW et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001;164: 103108.
  • 131
    Harari S, Simonneau G, DeJuli E, Brenot F, Cerrina J, Colombo P et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997;16: 460463.
  • 132
    King TE, Toose JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164: 11711181.
  • 133
    Schwartz DA, Van Fossen DS, Davis CS, Helmers RA, Dayton CS, Burmeister LF et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149: 444449.
  • 134
    Timmer SJ, Karamzadeh AM, Yung GL, Kriett J, Jamieson SW, Smith CM. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does PaO2 predict survival? Chest 2002;122: 779784.
  • 135
    Selman M. From anti-inflammatory drugs through antifibrotic agents to lung transplantation. Chest 2002;122: 759761.
  • 136
    Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987;135: 2634.
  • 137
    Peterson MW, Monick M, Hunninghake GW. Prognostic role of eosinophils in pulmonary fibrosis. Chest 1987;92: 5156.
  • 138
    Kirk JME, Bateman ED, Haslam PL, Laurent GL, Turner-Warwick M. Serum type III procollagen peptide concentrations in cryptogenic fibrosing alveolitis and its clinical relevance. Thorax 1984;39: 726732.
  • 139
    Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983;38: 349355.
  • 140
    Hiwatari N, Shimura S, Sasaki T, Aikawa T, Ando Y, Ishihara H et al. Prognosis of idiopathic pulmonary fibrosis in patients with mucous hypersecretion. Am Rev Respir Dis 1991;143: 182185.
  • 141
    McSweeny AJ, Creer TL. Health-related quality-of-life assessment in medical care. Disease-a-Month 1995;41: 171.
  • 142
    Gay SE, Kazerooni EA, Toews GB, Lynch JP, Gross BH, Cascade PN et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998;157: 10631072.
  • 143
    Jezek V, Fucik J, Michaljanic A, Jezkova L. The prognostic significance of functional tests in cryptogenic fibrosing alveolitis. Bull Eur Physiopath Resp 1980;16: 711720.
  • 144
    Erbes R, Schaber T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? Chest 1997;111: 5157.
  • 145
    van Oortegem K, Wallaert B, Marquette C, Ramon P, Perez T, Lafitte JJ et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994;7: 19501957.
  • 146
    Hanson D, Winterbauer R, Kirtland S, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108: 305310.
  • 147
    Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168: 10841090.
  • 148
    Fulmer J, Roberts W, von Gal E, Crystal R. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest 1979;63: 665676.
  • 149
    Cherniack R, Colby T, Flint A, Thurlbeck WM, Waldron JA Jr, Ackerson L et al. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;151: 11801188.
  • 150
    Watters L, King T, Schwarz M, Waldron J, Stanford R. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133: 97103.
  • 151
    King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr et al. Idiopathic pulmonary fibrosis. Relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164: 10251032.
  • 152
    Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166: 173177.
  • 153
    Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax 1999;54: 390395.
  • 154
    Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002;166: 839842.